Cargando…

UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure

OBJECTIVE: To assess persistence of immunity to hepatitis B (HBV) in primary school children vaccinated following perinatal exposure. DESIGN: Serological survey. SETTING: Five UK sites (Berkshire East, Birmingham, Buckinghamshire, Milton Keynes and Oxfordshire). PARTICIPANTS: Children from 3 years 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Yates, Tom A, Paranthaman, Karthikeyan, Yu, Ly-Mee, Davis, Elizabeth, Lang, Sarah, Hackett, Scott J, Welch, Steven B, Pollard, Andrew J, Snape, Matthew D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664378/
https://www.ncbi.nlm.nih.gov/pubmed/23476003
http://dx.doi.org/10.1136/archdischild-2012-302153
_version_ 1782271091746537472
author Yates, Tom A
Paranthaman, Karthikeyan
Yu, Ly-Mee
Davis, Elizabeth
Lang, Sarah
Hackett, Scott J
Welch, Steven B
Pollard, Andrew J
Snape, Matthew D
author_facet Yates, Tom A
Paranthaman, Karthikeyan
Yu, Ly-Mee
Davis, Elizabeth
Lang, Sarah
Hackett, Scott J
Welch, Steven B
Pollard, Andrew J
Snape, Matthew D
author_sort Yates, Tom A
collection PubMed
description OBJECTIVE: To assess persistence of immunity to hepatitis B (HBV) in primary school children vaccinated following perinatal exposure. DESIGN: Serological survey. SETTING: Five UK sites (Berkshire East, Birmingham, Buckinghamshire, Milton Keynes and Oxfordshire). PARTICIPANTS: Children from 3 years 4 months to 10 years of age (mean age 6.2 years), vaccinated against HBV from birth following perinatal exposure. INTERVENTIONS: A single booster dose of the paediatric formulation of a recombinant HBV vaccine. MAIN OUTCOME MEASURES: Titres of antibody against hepatitis B Surface Antigen (anti-HBs) measured immediately before and 21–35 days after the HBV vaccine booster. RESULTS: Prebooster anti-HBs titres were >10 mIU/ml in 84.6% of children (n=26; 95% CI 65.1 to 95.6%). All children (n=25, 95% CI 86.3 to 100%) had titres >100 mIU/ml after the booster. CONCLUSIONS: This study of antibody persistence among UK children born to hepatitis B infected women, immunised with a 3-dose infant schedule with a toddler booster suggests sustained immunity through early childhood. These data should prompt further studies to address the need for a preschool booster. TRIAL REGISTRATION: Eudract Number 2008-004785-98.
format Online
Article
Text
id pubmed-3664378
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36643782013-05-31 UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure Yates, Tom A Paranthaman, Karthikeyan Yu, Ly-Mee Davis, Elizabeth Lang, Sarah Hackett, Scott J Welch, Steven B Pollard, Andrew J Snape, Matthew D Arch Dis Child Original Article OBJECTIVE: To assess persistence of immunity to hepatitis B (HBV) in primary school children vaccinated following perinatal exposure. DESIGN: Serological survey. SETTING: Five UK sites (Berkshire East, Birmingham, Buckinghamshire, Milton Keynes and Oxfordshire). PARTICIPANTS: Children from 3 years 4 months to 10 years of age (mean age 6.2 years), vaccinated against HBV from birth following perinatal exposure. INTERVENTIONS: A single booster dose of the paediatric formulation of a recombinant HBV vaccine. MAIN OUTCOME MEASURES: Titres of antibody against hepatitis B Surface Antigen (anti-HBs) measured immediately before and 21–35 days after the HBV vaccine booster. RESULTS: Prebooster anti-HBs titres were >10 mIU/ml in 84.6% of children (n=26; 95% CI 65.1 to 95.6%). All children (n=25, 95% CI 86.3 to 100%) had titres >100 mIU/ml after the booster. CONCLUSIONS: This study of antibody persistence among UK children born to hepatitis B infected women, immunised with a 3-dose infant schedule with a toddler booster suggests sustained immunity through early childhood. These data should prompt further studies to address the need for a preschool booster. TRIAL REGISTRATION: Eudract Number 2008-004785-98. BMJ Publishing Group 2013-06 2013-03-09 /pmc/articles/PMC3664378/ /pubmed/23476003 http://dx.doi.org/10.1136/archdischild-2012-302153 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode
spellingShingle Original Article
Yates, Tom A
Paranthaman, Karthikeyan
Yu, Ly-Mee
Davis, Elizabeth
Lang, Sarah
Hackett, Scott J
Welch, Steven B
Pollard, Andrew J
Snape, Matthew D
UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure
title UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure
title_full UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure
title_fullStr UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure
title_full_unstemmed UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure
title_short UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure
title_sort uk vaccination schedule: persistence of immunity to hepatitis b in children vaccinated after perinatal exposure
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664378/
https://www.ncbi.nlm.nih.gov/pubmed/23476003
http://dx.doi.org/10.1136/archdischild-2012-302153
work_keys_str_mv AT yatestoma ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure
AT paranthamankarthikeyan ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure
AT yulymee ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure
AT daviselizabeth ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure
AT langsarah ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure
AT hackettscottj ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure
AT welchstevenb ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure
AT pollardandrewj ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure
AT snapematthewd ukvaccinationschedulepersistenceofimmunitytohepatitisbinchildrenvaccinatedafterperinatalexposure